<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Candida infections of the central nervous system</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Candida infections of the central nervous system</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Candida infections of the central nervous system</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John W Baddley, MD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 26, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Candida</em> infections of the central nervous system (CNS) most often involve the meninges. However, intracranial abscesses can occur either as an isolated phenomenon or associated with meningitis [<a href="#rid1">1,2</a>]. The abscesses are usually small microabscesses, multiple, and associated with disseminated infection in immunocompromised hosts [<a href="#rid3">3</a>].</p><p><em>Candida</em> meningitis can occur as a manifestation of disseminated candidiasis, which most often occurs in premature neonates [<a href="#rid4">4-6</a>], in the presence of ventricular drainage devices [<a href="#rid7">7-10</a>], and as isolated chronic meningitis [<a href="#rid3">3,11,12</a>]. In addition to hematogenous spread [<a href="#rid4">4,5,13</a>], <em>Candida</em> can enter the CNS at the time of craniotomy [<a href="#rid7">7</a>] or through a ventricular shunt [<a href="#rid7">7-10</a>].</p><p>The clinical features, diagnosis, and treatment of <em>Candida</em> meningitis and other CNS infections will be reviewed here. An overview of <em>Candida</em> infections is presented separately. Candidemia and invasive candidiasis are also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2416.html" rel="external">"Overview of Candida infections"</a> and  <a class="medical medical_review" href="/z/d/html/2442.html" rel="external">"Candidemia in adults: Epidemiology, microbiology, and pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/2462.html" rel="external">"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5976.html" rel="external">"Candidemia and invasive candidiasis in children: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6014.html" rel="external">"Candidemia and invasive candidiasis in children: Management"</a> and  <a class="medical medical_review" href="/z/d/html/5028.html" rel="external">"Epidemiology and risk factors for Candida infection in neonates"</a> and  <a class="medical medical_review" href="/z/d/html/5029.html" rel="external">"Treatment of Candida infection in neonates"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span><em>Candida</em> meningitis occurs most often in preterm neonates and following neurosurgical procedures [<a href="#rid4">4,5,7-10,14</a>]. In addition, patients who develop CNS infections are often immunocompromised [<a href="#rid3">3,12,13</a>]. Increased risk for development of CNS candidiasis has been described for patients who have a deficiency of the lectin receptor adaptor molecule CARD9, especially neonates and young children [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/5028.html" rel="external">"Epidemiology and risk factors for Candida infection in neonates"</a> and  <a class="medical medical_review" href="/z/d/html/5976.html" rel="external">"Candidemia and invasive candidiasis in children: Clinical manifestations and diagnosis", section on 'Risk factors'</a> and  <a class="medical medical_review" href="/z/d/html/2442.html" rel="external">"Candidemia in adults: Epidemiology, microbiology, and pathogenesis"</a>.)</p><p class="headingAnchor" id="H1833985779"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span><em>Candida</em> CNS infections are almost always due to <em>C. albicans</em> [<a href="#rid3">3,4</a>] but can occur with other species, such as <em>C. parapsilosis</em> and <em>C. tropicalis</em> [<a href="#rid9">9,13</a>]. <em>C. glabrata</em> is a rare cause of CNS infection [<a href="#rid4">4,9</a>]. (See  <a class="medical medical_review" href="/z/d/html/2442.html" rel="external">"Candidemia in adults: Epidemiology, microbiology, and pathogenesis", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H1833985676"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The symptoms of <em>Candida</em> meningitis may be the same as in patients with acute bacterial meningitis (eg, fever, stiff neck, altered mental status, headache). Less commonly, symptoms may be subacute to chronic as may be seen with tuberculous or cryptococcal meningitis. (See  <a class="medical medical_review" href="/z/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/128000.html" rel="external">"Tuberculous meningitis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2447.html" rel="external">"Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in patients without HIV"</a>.)</p><p>Fever may be the only manifestation in patients who are neutropenic, and signs of sepsis and multiorgan failure often predominate in neonates. Patients with multiple cerebral microabscesses can develop a diffuse encephalopathy [<a href="#rid3">3</a>].</p><p>In addition, among patients with hematogenous seeding, other signs of dissemination may be seen, such as endophthalmitis, endocarditis, skin lesions, and renal involvement [<a href="#rid3">3,16</a>]. (See  <a class="medical medical_review" href="/z/d/html/2462.html" rel="external">"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2446.html" rel="external">"Treatment of endogenous endophthalmitis and chorioretinitis due to Candida species"</a> and  <a class="medical medical_review" href="/z/d/html/2423.html" rel="external">"Candida endocarditis and suppurative thrombophlebitis"</a> and  <a class="medical medical_review" href="/z/d/html/2415.html" rel="external">"Candida infections of the bladder and kidneys"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Premature neonates</span><span class="headingEndMark"> — </span>The features of <em>Candida </em>meningitis in premature neonates were evaluated in a 10-year review of 106 patients with systemic candidiasis [<a href="#rid4">4</a>]. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Meningitis developed in 23 patients (22 percent) and was present in 0.4 percent of admissions to the neonatal intensive care unit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The median gestational age was 26 weeks and the median age at onset of clinical disease was eight days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The children were severely ill with respiratory decompensation, acidosis, and hypotension. A few patients had other signs of disseminated infection such as intracardiac vegetations, endophthalmitis, and hypoechogenic hepatic lesions on ultrasonography.</p><p></p><p>The clinical manifestations of <em>Candida </em>meningitis in neonates are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5024.html" rel="external">"Clinical manifestations and diagnosis of Candida infection in neonates", section on 'Central nervous system infection'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">CNS shunts and other devices</span><span class="headingEndMark"> — </span>Drainage-device infection usually occurs within several months of the surgical procedure and probably results from contamination during the procedure rather than hematogenous seeding of the device [<a href="#rid7">7-10</a>]. In a report that included three patients with neurosurgery-related <em>Candida</em> meningitis and that reviewed 15 others that were previously reported, most had received antibiotics and nine had a recent history of bacterial meningitis [<a href="#rid7">7</a>].</p><p>Another report evaluated 24 patients with <em>Candida</em> shunt infections, all but one of whom had a ventriculoperitoneal shunt [<a href="#rid8">8</a>]. The major predisposing factors were recent bacterial meningitis, neurosurgery other than shunt placement, and abdominal complications, such as intestinal perforation.</p><p>The symptoms and signs associated with <em>Candida</em> ventricular drainage device infections are similar to those seen with the more common bacterial infections of these devices [<a href="#rid7">7,8</a>]. In addition to fever, shunt malfunction can result in manifestations of increased intracranial pressure, such as headache, nausea, vomiting, and mental status changes. (See  <a class="medical medical_review" href="/z/d/html/1286.html" rel="external">"Infections of cerebrospinal fluid shunts"</a>.)</p><p>Among children, the CNS shunt is typically implanted in premature babies because of hydrocephalus. In a series of 48 CNS shunt infections in children, 8 (17 percent) were due to <em>Candida</em> spp [<a href="#rid9">9</a>]. The onset of infection ranged from one month to one year after shunt insertion. The clinical manifestations were subtle and slowly progressive.</p><p>Devices such as <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">carmustine</a> biopolymer wafers implanted to deliver chemotherapy to brain tumors and deep brain stimulators for the treatment of Parkinson disease and other movement disorders have been reported rarely to be infected with <em>Candida</em> spp [<a href="#rid17">17-19</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Chronic meningitis</span><span class="headingEndMark"> — </span>Chronic <em>Candida</em> meningitis occurs uncommonly and clinically resembles meningitis caused by tuberculosis or cryptococcosis. Patients can have illness for weeks to months before the diagnosis is made. In a review of 18 cases, headache, fever, and nuchal rigidity were the most common findings, but vomiting, confusion, visual disturbances, and cranial nerve palsies also were seen [<a href="#rid11">11</a>]. Five of the patients (28 percent) had no underlying illness or risk factor for candidiasis that were known.</p><p>In a review of 14 human immunodeficiency virus (HIV)-infected patients (median CD4 cell count 135/microL) with <em>Candida</em> meningitis [<a href="#rid12">12</a>], the major clinical features were headache and fever in the absence of focal neurologic symptoms.</p><p class="headingAnchor" id="H6"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The possible presence of CNS <em>Candida</em> infection should be suspected in patients with neurologic symptoms who have one or more of the following [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Isolation of <em>Candida</em> from the cerebrospinal fluid (CSF).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Isolation of <em>Candida</em> from another normally sterile site in patients who have pleocytosis on CSF analysis. Finding <em>Candida</em> species in blood cultures is helpful, but candidemia may not be documented in patients with <em>Candida</em> meningitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lack of adequate response of presumed bacterial or mycobacterial meningitis to appropriate therapy.</p><p></p><p class="headingAnchor" id="H7"><span class="h2">CSF analysis</span><span class="headingEndMark"> — </span>Lumbar puncture to obtain CSF for culture and analysis is essential for establishing the diagnosis. The overall rate of culture positivity is approximately 80 percent [<a href="#rid3">3</a>]. A positive CSF culture should not be considered a contaminant, particularly in immunocompromised patients; this is true even if other pathogens are identified [<a href="#rid3">3</a>].</p><p>In a review of neonatal infection, <em>Candida</em> was isolated from the CSF in 17 of 23 patients (74 percent) [<a href="#rid4">4</a>]. The initial CSF analysis was not always helpful. Twelve patients had a normal CSF white cell count. The mean CSF glucose concentration was 95 mg/dL (5.3 mmol/L), with only five patients having a glucose concentration below 45 mg/dL (2.5 mmol/L), and the mean CSF protein concentration was 214 mg/dL. The Gram stain was negative for yeast in all patients, and eight of the neonates had sterile blood cultures. (See  <a class="medical medical_review" href="/z/d/html/1285.html" rel="external">"Cerebrospinal fluid: Physiology and utility of an examination in disease states"</a>.)</p><p>The CSF findings are also variable in patients with neurosurgery-related <em>Candida</em> meningitis. Some have a neutrophilic pleocytosis similar to that seen in bacterial meningitis [<a href="#rid7">7</a>], whereas others have a lymphocytic predominance [<a href="#rid8">8</a>].</p><p>The diagnosis is more difficult in patients with chronic meningitis because the organism is present in low numbers and the yield of standard cultures of CSF is poor. In the above review of 18 cases, the following findings were noted [<a href="#rid11">11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>CSF analysis showed a mononuclear or neutrophilic pleocytosis, an elevated protein concentration, and reduced glucose concentration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The CSF smear was positive in only three patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The initial cultures were positive in eight patients. Use of special techniques resulted in the growth of <em>Candida</em> species in four patients, but the cultures remained negative in three.</p><p></p><p>In patients with chronic <em>Candida</em> meningitis, large-volume (10 to 20 mL) spinal taps are often required to obtain sufficient CSF for culture. The microbiology laboratory should be asked to culture the entire sample or to filter the sample through a Millipore filter and culture the filter on appropriate media. (See  <a class="medical medical_review" href="/z/d/html/1275.html" rel="external">"Approach to the patient with chronic meningitis", section on 'CSF examination and other laboratory testing'</a>.)</p><p>1,3-beta-D-glucan, a cell wall component of many fungi, is detected by the beta-D-glucan assay. The serum beta-D-glucan assay may be positive in patients with a variety of invasive fungal infections, including invasive candidiasis. Based upon a case report of <em>Candida </em>meningitis and experience with an outbreak of fungal meningitis related to injection of mold-contaminated <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>, the beta-D-glucan assay may also be useful in testing CSF as an adjunct to CSF cultures in patients with chronic <em>Candida</em> meningitis [<a href="#rid20">20,21</a>]. Importantly, this test can be positive in the setting of many different fungal infections, and cut-offs to define positivity in CSF are not defined. Test results must therefore be interpreted with caution. (See  <a class="medical medical_review" href="/z/d/html/2462.html" rel="external">"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults", section on 'Beta-D-glucan assay'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>Computed tomography (CT) can detect hydrocephalus, which is particularly common in patients with infected CNS shunts [<a href="#rid8">8,9</a>]. However, the CT scan is often normal and may not detect microabscesses [<a href="#rid3">3,13,22</a>]. In comparison, magnetic resonance imaging (MRI) can detect microabscesses, which appear as multiple, small, enhanced ring lesions, sometimes with a hemorrhagic component [<a href="#rid23">23</a>]. When such lesions are seen, MRI is also used to monitor the response to antifungal therapy. (See <a class="local">'Duration'</a> below.)</p><p class="headingAnchor" id="H9"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H10"><span class="h2">Antifungal therapy</span><span class="headingEndMark"> — </span>The standard initial therapy for <em>Candida</em> meningitis has been amphotericin B combined with <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> [<a href="#rid24">24</a>]. Amphotericin B is used because of its fungicidal activity against almost all <em>Candida</em> species, even though drug levels in the cerebrospinal fluid (CSF) and brain are low [<a href="#rid25">25,26</a>]. Flucytosine is added because of its anti-candidal activity and excellent penetration into CSF and brain tissue [<a href="#rid26">26</a>].</p><p>For the treatment of <em>Candida</em> CNS infections in adults, we recommend a lipid formulation of amphotericin B (5 mg/kg intravenously [IV] once daily) with or without <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> (<a class="graphic graphic_table graphicRef87680" href="/z/d/graphic/87680.html" rel="external">table 1</a>). <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">Liposomal amphotericin B</a> (AmBisome) is preferred because it appears to give higher concentrations in the brain compared with other lipid formulations or <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> [<a href="#rid24">24,25</a>].</p><p>In neonates, <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (1.0 mg/kg IV once daily) is the formulation used. Neonates tolerate the deoxycholate formulation better than adults, and there is little experience using the lipid formulations in this group [<a href="#rid4">4,27</a>]. <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">Flucytosine</a> is not recommended because adverse effects are frequent in neonates [<a href="#rid28">28</a>].</p><p>Therapy with an amphotericin B formulation with or without <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> should continue for several weeks until clinical improvement as well as improvement in the CSF profile has occurred. We favor repeating the lumbar puncture weekly until the white blood cell count decreases and the culture no longer yields <em>Candida</em>.</p><p><a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">Flucytosine</a> (5-FC) is given at a dose of 25 mg/kg orally four times per day in patients with normal renal function. Careful attention to serum levels is warranted to avoid bone marrow toxicity, particularly in patients with renal dysfunction. When available, monitoring of serum 5-FC concentrations is recommended after three to five doses of therapy, and should be obtained two hours after a dose has been administered. The target peak concentration is between 50 and 80 mcg/mL; concentrations &gt;100 mcg/mL should be avoided. Serum drug concentrations should be repeated if renal function worsens or if leukopenia or thrombocytopenia occurs. With decreasing renal function (often due to amphotericin B), toxicity is more common and patients must be monitored particularly carefully. If amphotericin B–induced nephrotoxicity occurs, the dose of flucytosine should be reduced.</p><p>All patients receiving <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> should undergo regular monitoring of complete blood counts (CBC). In settings in which serum flucytosine concentrations are not available, CBC monitoring two to three times per week provides an indirect method of screening for excessive dosing. An otherwise unexplained reduction in the neutrophil or platelet count may reflect flucytosine toxicity and the dose should be reduced immediately. (See  <a class="medical medical_review" href="/z/d/html/472.html" rel="external">"Pharmacology of flucytosine (5-FC)", section on 'Serum concentration monitoring'</a> and  <a class="medical medical_review" href="/z/d/html/2364.html" rel="external">"Amphotericin B nephrotoxicity"</a>.)</p><p><a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a> has excellent CNS penetration and is active against most <em>Candida</em> isolates causing CNS infections [<a href="#rid29">29</a>]. However, treatment outcomes have varied with the use of fluconazole alone or in combination with <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> [<a href="#rid9">9-11,30</a>]. In patients infected with a fluconazole-susceptible <em>Candida</em> spp, we recommend that oral fluconazole be used as step-down therapy after an initial several-week course of <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> with or without flucytosine [<a href="#rid11">11,24</a>]. In adult patients with a normal serum creatinine, oral fluconazole should be given at a dose of 400 to 800 mg (6 to 12 mg/kg) daily. Since fluconazole is highly bioavailable, oral therapy is appropriate for most patients. Intravenous therapy (at the same dose) should be given to patients who are unable to take oral medications, who are not expected to have good gastrointestinal absorption, or who are severely ill.</p><p><a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">Voriconazole</a> achieves excellent CSF concentrations and is active against most <em>Candida</em> species causing CNS infection. However, clinical experience with voriconazole for <em>Candida</em> CNS infections is limited. It can be useful as step-down therapy, but not initial therapy, for the rare cases of CNS infections due to <em>C. krusei</em> or <em>C. glabrata</em>. Most strains of <em>C. krusei</em> are susceptible to voriconazole. However, voriconazole cannot be used for <em>C. glabrata </em>unless susceptibility testing verifies that the organism is susceptible, as this species is frequently resistant, or can become resistant, to all azoles.</p><p><a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">Posaconazole</a> does not achieve adequate CSF levels [<a href="#rid24">24,31</a>], and there is little experience in using this agent for invasive candidiasis. Therefore, posaconazole is not recommended for the treatment of CNS <em>Candida</em> infections.</p><p>Data of <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">isavuconazole</a> concentrations in human brain tissue and CSF are scarce [<a href="#rid32">32,33</a>]. In a systematic review of 36 individuals with CNS fungal infections treated with isavuconazole as primary or salvage therapy, 21 (58 percent) had complete or partial clinical response [<a href="#rid34">34</a>]. However, none of the patients had CNS <em>Candida</em> infection. Isavuconazole is not recommended for treatment of <em>Candida</em> CNS infections.</p><p><a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">Caspofungin</a> and the other echinocandins do not achieve adequate CSF concentrations to treat <em>Candida</em> meningitis [<a href="#rid35">35</a>]. In a case report, new cerebral abscesses developed in a patient being treated with caspofungin for <em>Candida</em> endocarditis [<a href="#rid36">36</a>]. There are experimental animal studies showing the effectiveness of <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">anidulafungin</a> and <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">micafungin</a> for CNS <em>Candida</em> infections, but the dosages used far exceed those recommended in humans [<a href="#rid37">37,38</a>]. The echinocandins should not be used for CNS candidiasis.</p><p class="headingAnchor" id="H11"><span class="h3">Duration</span><span class="headingEndMark"> — </span>Antifungal therapy should continue until all abscesses, if seen at presentation, have resolved on magnetic resonance imaging (MRI); the CSF glucose, pleocytosis, protein, and culture have returned to normal; and the patient's symptoms and signs have resolved [<a href="#rid24">24</a>]. It may take weeks to months for the above measures to be accomplished, especially in patients with chronic <em>Candida </em>meningitis.</p><p>There are no data available concerning the frequency of testing, but the following approach seems reasonable:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with cerebral abscesses, MRI should be repeated at two weeks (or earlier if the patient is deteriorating) and then monthly until resolution.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with acute meningitis, lumbar puncture should be repeated weekly for the first few weeks to be sure that the CSF changes are returning toward normal and that cultures are negative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with chronic meningitis, lumbar puncture should be repeated as for acute meningitis. The best parameters to follow are the CSF white cell count and protein and glucose concentrations. Because the organism is present in low numbers and the yield of standard cultures of CSF is poor, a negative CSF culture is not adequate to determine response to therapy [<a href="#rid11">11</a>].</p><p></p><p>Patients who have cerebral abscesses, are markedly immunocompromised, or have chronic <em>Candida</em> meningitis need longer courses of therapy, and patients who have infected ventricular shunts or implantable CNS devices must have the device removed to achieve cure of the infection [<a href="#rid7">7-9,24</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Removal of CNS devices</span><span class="headingEndMark"> — </span>Infected ventricular devices should be removed [<a href="#rid24">24</a>]. Other implanted devices, such as deep brain stimulators and <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">carmustine</a> biopolymer wafers used for chemotherapy, should also be removed if possible [<a href="#rid17">17-19</a>]. Systemic antifungal therapy should also be administered to patients with infected ventricular devices, as discussed above. (See <a class="local">'Antifungal therapy'</a> above.) </p><p>If it is not possible to remove a ventricular device, we suggest administering <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> through the device into the ventricle at a dose of 0.01 to 0.5 mg in 2 mL 5% dextrose in water [<a href="#rid24">24</a>]. Toxicity (headache, nausea, vomiting) is a limiting factor. (See  <a class="medical medical_review" href="/z/d/html/476.html" rel="external">"Pharmacology of amphotericin B", section on 'Intrathecal'</a>.) </p><p class="headingAnchor" id="H13"><span class="h1">MORTALITY</span><span class="headingEndMark"> — </span>Data on mortality comes from the relatively small case series described above. The following illustrate the range of findings in the different settings noted above (neonates, neurosurgery patients, and chronic meningitis):</p><p class="bulletIndent1"><span class="glyph">●</span>In a review of 320 neonates with birth weights &lt;1000 grams, 27 had meningitis, 15 of whom had neurodevelopmental parameters tested at 18 to 22 months of age [<a href="#rid28">28</a>]. In this small cohort, 53.3 percent had neurodevelopmental impairment documented, and 29.6 percent died.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In two reviews with a total of 40 neurosurgical patients with <em>Candida</em> meningitis, 4 died (10 percent) [<a href="#rid7">7,8</a>]. In one series, 1 of the deaths was in the only patient among the 22 total patients in whom the shunt was not removed [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the review of 18 patients with chronic <em>Candida</em> meningitis, the overall mortality was 53 percent [<a href="#rid11">11</a>]. However, among the 12 patients who were appropriately treated and followed, only 4 (33 percent) died. A similar mortality (31 percent) has been noted in HIV-infected patients with chronic <em>Candida</em> meningitis [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H2179230485"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/104270.html" rel="external">"Society guideline links: Candidiasis"</a>.)</p><p class="headingAnchor" id="H1833985349"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p><strong>Epidemiology and clinical features</strong></p><p class="bulletIndent1"><span class="glyph">●</span><em>Candida</em> infections of the central nervous system (CNS) most often involve the meninges. However, intracranial abscesses can occur either as an isolated phenomenon or associated with meningitis. The abscesses are usually small microabscesses, multiple, and associated with disseminated infection in immunocompromised hosts. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Candida</em> meningitis can occur as a manifestation of disseminated candidiasis, which most often occurs in premature neonates, in the presence of ventricular drainage devices, and as isolated chronic meningitis. In addition to hematogenous spread, <em>Candida</em> can enter the CNS at the time of craniotomy or through a ventricular shunt. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As with <em>Candida</em> infections at most other sites, patients who develop CNS infections are usually immunocompromised. Most cases occur in preterm neonates and after neurosurgery. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The symptoms of <em>Candida</em> meningitis can be the same as in patients with acute bacterial meningitis (eg, fever, stiff neck, altered mental status, headache). Fever may be the only manifestation in patients who are neutropenic, whereas signs of sepsis and multiorgan failure often predominate in neonates. Symptoms in patients with chronic <em>Candida </em>meningitis may be subtle and persist for weeks to months prior to diagnosis. Patients with multiple cerebral microabscesses can develop a diffuse encephalopathy. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drainage device infection usually occurs within several months of the surgical procedure and probably results from implantation during the procedure rather than hematogenous seeding of the device. The symptoms and signs associated with <em>Candida</em> ventricular drainage device infections are similar to those seen with the more common bacterial infections of these devices. In addition to fever, shunt malfunction can result in manifestations of increased intracranial pressure, such as headache, nausea, vomiting, and mental status changes. (See <a class="local">'CNS shunts and other devices'</a> above.)</p><p></p><p><strong>Diagnosis</strong></p><p class="bulletIndent1"><span class="glyph">●</span>The possible presence of CNS <em>Candida</em> infection should be suspected in patients with neurologic symptoms who have one or more of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Isolation of <em>Candida</em> from the cerebrospinal fluid (CSF).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Isolation of <em>Candida</em> from another normally sterile site in patients who have pleocytosis on CSF analysis. Finding <em>Candida</em> species in blood cultures is helpful, but candidemia may not be documented in patients with <em>Candida</em> meningitis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lack of adequate response of presumed bacterial or mycobacterial meningitis to appropriate therapy (see <a class="local">'Diagnosis'</a> above).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lumbar puncture to obtain CSF for culture and analysis is essential for establishing the diagnosis. The beta-D-glucan assay using CSF might be a useful adjunct to CSF culture and analysis. (See <a class="local">'CSF analysis'</a> above.)</p><p></p><p><strong>Treatment</strong></p><p class="bulletIndent1"><span class="glyph">●</span>For the treatment of <em>Candida</em> CNS infections in adults, we recommend <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> (5 mg/kg intravenously [IV] once daily) with or without <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> (25 mg/kg orally four times daily) (<a class="graphic graphic_table graphicRef87680" href="/z/d/graphic/87680.html" rel="external">table 1</a>) (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). For neonates, we recommend <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>, 1 mg/kg IV once daily (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). (See <a class="local">'Antifungal therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Therapy with an amphotericin B formulation with or without <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> should continue for at least a few weeks and until the patient has shown clinical improvement as well as improvement in the CSF profile has been noted. We favor repeating the lumbar puncture weekly to ascertain that the white blood cell count is decreasing and that culture no longer yields <em>Candida</em>. In patients infected with a fluconazole-susceptible <em>Candida</em> strain, we recommend that oral <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> be used as step-down therapy after the initial course of amphotericin B with or without flucytosine (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). (See <a class="local">'Antifungal therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antifungal therapy should continue until all abscesses, if seen at presentation, have resolved on magnetic resonance imaging; the CSF glucose, pleocytosis, protein, and culture have returned to normal; and the patient's symptoms and signs have resolved. It may take weeks to months for the above measures to be accomplished. (See <a class="local">'Duration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infected ventricular devices should be removed. Other implanted devices, such as deep brain stimulators and <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">carmustine</a> biopolymer wafers used for chemotherapy, should also be removed if possible. Systemic antifungal therapy should be administered to patients with infected ventricular devices, as discussed above. If it is not possible to remove a ventricular device, we suggest administering <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> through the device into the ventricle at a dose of 0.01 to 0.5 mg in 2 mL 5% dextrose in water (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Removal of CNS devices'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mattiuzzi G, Giles FJ. Management of intracranial fungal infections in patients with haematological malignancies. Br J Haematol 2005; 131:287.</a></li><li><a class="nounderline abstract_t">Fennelly AM, Slenker AK, Murphy LC, et al. Candida cerebral abscesses: a case report and review of the literature. Med Mycol 2013; 51:779.</a></li><li><a class="nounderline abstract_t">Sánchez-Portocarrero J, Pérez-Cecilia E, Corral O, et al. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis 2000; 37:169.</a></li><li><a class="nounderline abstract_t">Fernandez M, Moylett EH, Noyola DE, Baker CJ. Candidal meningitis in neonates: a 10-year review. Clin Infect Dis 2000; 31:458.</a></li><li><a class="nounderline abstract_t">Lee BE, Cheung PY, Robinson JL, et al. Comparative study of mortality and morbidity in premature infants (birth weight, &lt; 1,250 g) with candidemia or candidal meningitis. Clin Infect Dis 1998; 27:559.</a></li><li><a class="nounderline abstract_t">Cohen-Wolkowiez M, Smith PB, Mangum B, et al. Neonatal Candida meningitis: significance of cerebrospinal fluid parameters and blood cultures. J Perinatol 2007; 27:97.</a></li><li><a class="nounderline abstract_t">Nguyen MH, Yu VL. Meningitis caused by Candida species: an emerging problem in neurosurgical patients. Clin Infect Dis 1995; 21:323.</a></li><li><a class="nounderline abstract_t">Sánchez-Portocarrero J, Martín-Rabadán P, Saldaña CJ, Pérez-Cecilia E. Candida cerebrospinal fluid shunt infection. Report of two new cases and review of the literature. Diagn Microbiol Infect Dis 1994; 20:33.</a></li><li><a class="nounderline abstract_t">Chiou CC, Wong TT, Lin HH, et al. Fungal infection of ventriculoperitoneal shunts in children. Clin Infect Dis 1994; 19:1049.</a></li><li><a class="nounderline abstract_t">Cruciani M, Di Perri G, Molesini M, et al. Use of fluconazole in the treatment of Candida albicans hydrocephalus shunt infection. Eur J Clin Microbiol Infect Dis 1992; 11:957.</a></li><li><a class="nounderline abstract_t">Voice RA, Bradley SF, Sangeorzan JA, Kauffman CA. Chronic candidal meningitis: an uncommon manifestation of candidiasis. Clin Infect Dis 1994; 19:60.</a></li><li><a class="nounderline abstract_t">Casado JL, Quereda C, Oliva J, et al. Candidal meningitis in HIV-infected patients: analysis of 14 cases. Clin Infect Dis 1997; 25:673.</a></li><li><a class="nounderline abstract_t">McCullers JA, Vargas SL, Flynn PM, et al. Candidal meningitis in children with cancer. Clin Infect Dis 2000; 31:451.</a></li><li><a class="nounderline abstract_t">O'Brien D, Stevens NT, Lim CH, et al. Candida infection of the central nervous system following neurosurgery: a 12-year review. Acta Neurochir (Wien) 2011; 153:1347.</a></li><li><a class="nounderline abstract_t">Drummond RA, Lionakis MS. Candidiasis of the Central Nervous System in Neonates and Children with Primary Immunodeficiencies. Curr Fungal Infect Rep 2018; 12:92.</a></li><li><a class="nounderline abstract_t">Lipton SA, Hickey WF, Morris JH, Loscalzo J. Candidal infection in the central nervous system. Am J Med 1984; 76:101.</a></li><li><a class="nounderline abstract_t">O'Brien D, Cotter M, Lim CH, et al. Candida parapsilosis meningitis associated with Gliadel (BCNU) wafer implants. Br J Neurosurg 2011; 25:289.</a></li><li><a class="nounderline abstract_t">Pepper J, Zrinzo L, Mirza B, et al. The risk of hardware infection in deep brain stimulation surgery is greater at impulse generator replacement than at the primary procedure. Stereotact Funct Neurosurg 2013; 91:56.</a></li><li><a class="nounderline abstract_t">Glick JA, Graham RS, Voils SA. Candida meningitis post Gliadel wafer placement successfully treated with intrathecal and intravenous amphotericin B. Ann Pharmacother 2010; 44:215.</a></li><li><a class="nounderline abstract_t">Lyons JL, Erkkinen MG, Vodopivec I. Cerebrospinal fluid (1,3)-β-D-glucan in isolated Candida meningitis. Clin Infect Dis 2015; 60:161.</a></li><li><a class="nounderline abstract_t">Malani AN, Singal B, Wheat LJ, et al. (1,3)-β-d-glucan in cerebrospinal fluid for diagnosis of fungal meningitis associated with contaminated methylprednisolone injections. J Clin Microbiol 2015; 53:799.</a></li><li><a class="nounderline abstract_t">Pendlebury WW, Perl DP, Munoz DG. Multiple microabscesses in the central nervous system: a clinicopathologic study. J Neuropathol Exp Neurol 1989; 48:290.</a></li><li><a class="nounderline abstract_t">Lai PH, Lin SM, Pan HB, Yang CF. Disseminated miliary cerebral candidiasis. AJNR Am J Neuroradiol 1997; 18:1303.</a></li><li><a class="nounderline abstract_t">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a class="nounderline abstract_t">Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000; 182:274.</a></li><li><a class="nounderline abstract_t">Slavoski LA, Tunkel AR. Therapy of fungal meningitis. Clin Neuropharmacol 1995; 18:95.</a></li><li><a class="nounderline abstract_t">van den Anker JN, van Popele NM, Sauer PJ. Antifungal agents in neonatal systemic candidiasis. Antimicrob Agents Chemother 1995; 39:1391.</a></li><li><a class="nounderline abstract_t">Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006; 117:84.</a></li><li><a class="nounderline abstract_t">Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36:630.</a></li><li><a class="nounderline abstract_t">Epelbaum S, Laurent C, Morin G, et al. Failure of fluconazole treatment in Candida meningitis. J Pediatr 1993; 123:168.</a></li><li><a class="nounderline abstract_t">Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005; 5:775.</a></li><li><a class="nounderline abstract_t">Rouzaud C, Jullien V, Herbrecht A, et al. Isavuconazole Diffusion in Infected Human Brain. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Lamoth F, Mercier T, André P, et al. Isavuconazole brain penetration in cerebral aspergillosis. J Antimicrob Chemother 2019; 74:1751.</a></li><li><a class="nounderline abstract_t">Schwartz S, Cornely OA, Hamed K, et al. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system. Med Mycol 2020; 58:417.</a></li><li><a class="nounderline abstract_t">Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36:1445.</a></li><li><a class="nounderline abstract_t">Prabhu RM, Orenstein R. Failure of caspofungin to treat brain abscesses secondary to Candida albicans prosthetic valve endocarditis. Clin Infect Dis 2004; 39:1253.</a></li><li><a class="nounderline abstract_t">Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008; 197:163.</a></li><li><a class="nounderline abstract_t">Warn PA, Livermore J, Howard S, et al. Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. Antimicrob Agents Chemother 2012; 56:708.</a></li></ol></div><div id="topicVersionRevision">Topic 2453 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16225648" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Management of intracranial fungal infections in patients with haematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23651179" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Candida cerebral abscesses: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10904190" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The central nervous system and infection by Candida species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10987705" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Candidal meningitis in neonates: a 10-year review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9770157" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparative study of mortality and morbidity in premature infants (birth weight,&lt;1,250 g) with candidemia or candidal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17080094" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Neonatal Candida meningitis: significance of cerebrospinal fluid parameters and blood cultures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8562739" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Meningitis caused by Candida species: an emerging problem in neurosurgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7867296" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Candida cerebrospinal fluid shunt infection. Report of two new cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7888533" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fungal infection of ventriculoperitoneal shunts in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1486898" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Use of fluconazole in the treatment of Candida albicans hydrocephalus shunt infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7948559" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Chronic candidal meningitis: an uncommon manifestation of candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9314460" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Candidal meningitis in HIV-infected patients: analysis of 14 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10987704" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Candidal meningitis in children with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21431456" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Candida infection of the central nervous system following neurosurgery: a 12-year review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30393511" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Candidiasis of the Central Nervous System in Neonates and Children with Primary Immunodeficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6691350" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Candidal infection in the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21158511" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Candida parapsilosis meningitis associated with Gliadel (BCNU) wafer implants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23207787" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The risk of hardware infection in deep brain stimulation surgery is greater at impulse generator replacement than at the primary procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20028954" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Candida meningitis post Gliadel wafer placement successfully treated with intrathecal and intravenous amphotericin B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25228700" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cerebrospinal fluid (1,3)-β-D-glucan in isolated Candida meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25540391" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : (1,3)-β-d-glucan in cerebrospinal fluid for diagnosis of fungal meningitis associated with contaminated methylprednisolone injections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2649643" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Multiple microabscesses in the central nervous system: a clinicopathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9282859" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Disseminated miliary cerebral candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10882607" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8635178" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Therapy of fungal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7492074" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Antifungal agents in neonatal systemic candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16396864" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12594645" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Voriconazole: a new triazole antifungal agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8320615" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Failure of fluconazole treatment in Candida meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16310149" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Posaconazole: a broad-spectrum triazole antifungal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31405852" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Isavuconazole Diffusion in Infected Human Brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30753519" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Isavuconazole brain penetration in cerebral aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31613363" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12766841" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Caspofungin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15486856" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Failure of caspofungin to treat brain abscesses secondary to Candida albicans prosthetic valve endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18171300" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22123680" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
